Mechanistically, research shows that GLP-1 agonists can modulate the gut microbiome composition, enhance intestinal barrier function through increased mucin production, and reduce inflammatory cytokines implicated in IBS pathogenesis
I'm in my third month taking GLP-1 weekly and am seeing great results
503B facilities may dispense directly to patients, but they primarily distribute to prescribers, clinics, pharmacies, hospitals and health care facilities
however, this strategy has been associated with limited success
This story shows how dangerous unregulated substances can be and why investigative journalism matters
For context, if you are following a semaglutide 5mg/mL dosage chart but your product is actually 7% pure, the math breaks down completely